Francesco Md Boselli

Francesco Md Boselli

Auto-generated profile, based on publicly available information

Francesco Md Boselli

Ophthalmology Department, “Fondazione Policlinico Universitario A. Gemelli, IRCCS”, Rome, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2024 in Ophthalmology Science
Verified
Journal Article
Open access
SRStanislao Rizzo
Stanislao Rizzo
MSMaria Cristina Savastano
Maria Cristina Savastano
Benedetto FalsiniBenedetto Falsini
Benedetto Falsini
PBPatrizio Bernardinelli
Patrizio Bernardinelli
FBFrancesco Boselli
Francesco Boselli
ASAlfonso Savastano
Alfonso Savastano
To evaluate the safety of subretinal injection of cord blood platelet-rich plasma (CB-PRP) and its possible effect in eyes affected by geographic atrophy (GA) associated with dry age-related macular degeneration (d-AMD). Interventional, open-label study started in January 2021 with follow-up at 12 months (the Si.Cord Study). This study was a single-center, nonrandomized, sequential-assigned clinical trial conducted in Rome, Italy, at Fondazione Policlinico Universitario Agostino Gemelli IRCCS (ClinicalTrials.gov NCT04636853). Thirteen patients (26 eyes) with bilateral d-AMD-related GA were enrolled. One eye from each patient (with more advanced GA) underwent CB-PRP treatment, and the fellow eye was considered the control. All patients participated in follow-up at 12 months. All 13 eyes received 23-gauge (G) vitrectomy and subretinal injection of CB-PRP using a 41-gauge needle. Best-corrected visual acuity (BCVA) with ETDRS letters, central macular thickness using OCT, and atrophic area measured on en face OCT images were assessed at baseline, 1, 3, 6, and 12 months. The BCVA in the treated group was 34.46 ± 20.8 ETDRS at baseline, 40.84 ± 20.52 at 1 month, 40.07 ± 20.34 at 3 months, 39.38 ± 19.84 at 6 months, and 35.84 ± 18.38 at 12 months. In the untreated group, the BCVA was 53 ± 21.1 ETDRS letters at baseline, 51.54 ± 20.99 at 1 month, 46.62 ± 19.47 at 3 months, 46.85 ± 18.58 at 6 months, and 43.92 ± 17.97 at 12 months (2-way analysis of variance: interaction of treatment by eye or time, P = 0.084). Central macular thickness did not show a significant intereye difference at 12 months (P = 0.97). The atrophic geographic areas tended to increase in both treated and fellow eyes at 12 months (P < 0.0001). No inflammatory reaction, endophthalmitis, retinal detachment, uveitis, or other complications due to the subretinal injection of CB-PRP were observed during the follow-up. Subretinal injection of CB-PRP could be safely used for d-AMD in its GA form. Despite its safety, a larger cohort of patients, and probably a new way of administration, will be needed to understand whether the CB-PRP could have a role in the GA treatment. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

1 April 2025 in Retina
Verified
Journal Article
Open access
MCMatteo Mario Md Carlà
Matteo Mario Md Carlà
FBFrancesco Md Boselli
Francesco Md Boselli
FGFederico Md Giannuzzi
Federico Md Giannuzzi
ECEmanuele Md Crincoli
Emanuele Md Crincoli
MCMattia Cusato
Mattia Cusato
SRStanislao Rizzo
Stanislao Rizzo
Purpose: The aim of this review was to summarize the most recent investigations on perifoveal exudative vascular anomalous complex (PEVAC) lesions and guide future research of this entity. Methods: Retrospective analysis of Cochrane Central, PubMed, Web of Science, and ClinicalTrials.gov databases for papers regarding PEVAC, looking for the following keywords: “perifoveal exudative anomalous vascular complex,” “PEVAC,” “PVAC,” “nePVAC,” “ePVAC,” “deep retinal age-related microvascular anomalies,” and “DRAMA.” Results: PEVACs are described as a single, massive, unilateral aneurysm that frequently present with intraretinal cystic edema surrounding the fovea, active exudation and hemorrhages, usually in healthy patients. Notwithstanding this, association with age-related macular degeneration, myopia, diabetes, lamellar hole, and pachychoroid pigment epitheliopathy are frequently reported. Currently, a multimodal imaging is warranted, especially the use of OCT and OCTA can rule out several other differential diagnoses. Because of the uncertainty of the pathophysiological mechanism, the right management of these lesions are yet to be clear. Overall, laser therapy has been effective in several reports, both with thermal and micropulse type. Anti–vascular endothelial growth factor injections and steroid injections demonstrated a nonconstant response. Conclusion: Several new findings are revolutionizing PEVAC management. Greater standardization could help understand the correct treatment of these lesions.